CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Anti-SARS-CoV2 serological controls and serum neutralizationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug992 Gas exchanges at different PEEP Wiki 1.00
drug1046 Hemodynamics changes at different PEEP Wiki 1.00
drug2875 lung mechanics at different PEEP Wiki 1.00
drug185 Anti-SARS-CoV2 Serology Wiki 0.71
drug1978 Questionnaire Wiki 0.21

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110)

In mid-February 2020, within the Oise (France) cluster, a case of COVID-19 disease caused by a SARS-CoV2 infection was described among the personnel of the Creail Air Force Base (BA110). This resulted in the beginning of an epidemic controlled by epidemiological measures. One month later, containment measures were taken at the national level, measures that also applied to BA110 personnel. These personnel, exposed to both the initial phase of the epidemic and national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus, particularly at a time when France is lifting the containment measures. It becomes extremely important to understand the levers of viral spread in order to adjust the health measures to be maintained as best as possible. The main objective of this study is to determine the extent of virus diffusion in this highly circulating population, as evidenced by several identified cases of COVID-19.

NCT04404270 Sars-CoV2 Diagnostic Test: Anti-SARS-CoV2 Serology Behavioral: Questionnaire Diagnostic Test: Anti-SARS-CoV2 serological controls and serum neutralization

Primary Outcomes

Description: The percentage of the study population with positive serological status will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0

Measure: Proportion anti-SARS-CoV2 seropositive

Time: Day 0

Secondary Outcomes

Description: Among anti-SARS-CoV2 seropositive participants, the percentage of asymptomatic participants will be determined. COVID-19 symptoms will be measured using a questionnaire.

Measure: Proportion of asymptomatic anti-SARS-CoV2 seropositive participants

Time: Day 0

Description: The serological results obtained using the reference ELISA test results (detecting the presence of IgG and IgM antobodies) and using a second ELISA test detecting the presence of antibodies specifically directed against the Receptor Binding Domain and the Spike protein trimer of SARS-CoV2 virus will be compared.

Measure: Agreement between the anti-SARS-CoV2 serological results obtained using two different techniques (detecting the presence of different antibodies)

Time: Day 0

Description: Among anti-SARS-CoV2 seropositive participants, the percentage of participants with a positive response to serum neutralization will be determined.

Measure: Proportion of serum neutralization positive

Time: Day 0

Description: The evolution of the antibody level over time will be determined using repeated serodiagnoses at 3 and 9 months.

Measure: Change of antibody level over time

Time: 3 months and 9 months after Day 0

No related HPO nodes (Using clinical trials)